secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-10-05T23:59:59+00:00
Accession:  0001193125-22-257937
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.
- ETX-155 60mg single-dose exposures in Phase 1 PK trial consistent with prior trials; low PSE exposures within previously reported variability.
- Company to evaluate 75mg repeat dose in ongoing Phase 1 PK trial; final results expected Q4 2022.
- Phase 2a MDD trial to initiate Q1 2023; topline data mid-2024. PSE trial not reinitiated; FOS development continues.
- Kv7 program: two pre-candidates scaling up for IND-enabling studies Q1 2023; Phase 1 studies H1 2024. GAD program discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/0001193125-22-257937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522257937/d401397d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-257937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer